FDA Class II Recall: Micro Labs Limited's Clobazam Tablets Face CGMP Deviations, Prompting Supply Chain Scrutiny
Micro Labs Limited has initiated a Class II recall for 24,768 bottles of Clobazam Tablets 10mg due to CGMP deviations, specifically out-of-specification residual solvents. This event, impacting nationwide U.S. distribution, signals significant quality control vulnerabilities for the Indian manufacturer. Procurement and regulatory teams must assess immediate supply risks and potential long-term implications for sourcing this critical benzodiazepine.
FDA Mandates Class II Recall for Micro Labs Limited's Clobazam Due to CGMP Deviations
The U.S. Food and Drug Administration (FDA) has classified a voluntary recall initiated by Micro Labs Limited for its Clobazam Tablets 10mg as Class II, underscoring a significant regulatory event for the global pharmaceutical supply chain. This recall, identified as D-0348-2024, commenced on February 12, 2024, and targets 24,768 bottles of the 100-count prescription-only product, distributed nationwide across the USA. The core issue stems from Current Good Manufacturing Practice (CGMP) deviations, specifically the product being 'out of specification for residual solvents.' For procurement directors, this immediately signals a critical quality control failure at the manufacturing source, necessitating an urgent review of existing Clobazam supply contracts and inventory. Regulatory affairs heads must recognize that such deviations indicate a breakdown in fundamental quality systems, which could trigger enhanced FDA scrutiny beyond the immediate recall action. The presence of residual solvents above acceptable limits poses potential safety concerns and directly impacts product quality and efficacy, making this a high-priority concern for any business relying on this supply chain.
Manufacturing Facility and Affected Product Profile: Verna, India Site Under Scrutiny
The recalled Clobazam Tablets 10mg (NDC 42571-315-01, also affecting 42571-316) are manufactured by Micro Labs Limited at its facility in Verna, India, located at Plot# S - 155 & N1 Phase Iii & Phase Iv, Verna Ind Estate Road. This facility is responsible for producing Clobazam, a human prescription drug administered orally, which is classified as a Benzodiazepine. Clobazam is known for its pharmacological actions as a Cytochrome P450 2D6 Inhibitor and a Cytochrome P450 3A4 Inducer. The specific application number associated with this product is ANDA211711. For supply chain VPs, this incident highlights the inherent risks associated with single-source manufacturing or heavy reliance on specific geographical hubs, particularly for active pharmaceutical ingredients (APIs) and finished drug products. The recall of a widely distributed benzodiazepine from a key Indian manufacturing site underscores the need for robust supplier qualification and continuous monitoring programs. Businesses must assess their exposure to this specific facility and understand the broader implications for their global sourcing strategies, especially concerning products manufactured in regions prone to increased regulatory oversight.
Commercial Impact and Supply Chain Exposure for US Market
The nationwide distribution of 24,768 bottles of Clobazam Tablets 10mg from Micro Labs Limited carries significant commercial implications for the U.S. pharmaceutical market. This volume represents a substantial presence, and its removal due to CGMP deviations creates an immediate supply gap that procurement directors must address. Any company involved in the distribution, dispensing, or further formulation of Clobazam sourced from Micro Labs Limited is directly exposed to this recall. Business development executives should note the potential market disruption, which could present opportunities for alternative suppliers or competitors to capture market share if Micro Labs Limited faces prolonged manufacturing issues or regulatory sanctions. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, but the commercial impact of product unavailability and reputational damage remains substantial. Supply chain VPs must quickly identify all affected inventory, initiate return procedures, and communicate proactively with downstream partners to minimize disruption and maintain patient safety.
Strategic Sourcing: Identifying Alternative Clobazam Suppliers
Given the Class II recall of Micro Labs Limited's Clobazam Tablets, procurement teams must immediately prioritize identifying and qualifying alternative suppliers to ensure continuity of supply for this critical benzodiazepine. Our intelligence indicates no specific alternative suppliers for Clobazam are currently listed in the knowledge graph context for Micro Labs Limited, which underscores the urgency and complexity of this task. This situation necessitates a comprehensive global search for manufacturers capable of producing Clobazam (UNII: 2MRO291B4U) to FDA CGMP standards. Qualification timelines for new pharmaceutical suppliers, especially for controlled substances like Clobazam, can extend significantly, often requiring several months for audits, documentation review, and analytical validation. Regulatory affairs heads should prepare for potential changes to existing drug master files (DMFs) or even new abbreviated new drug application (ANDA) submissions if a new primary supplier is identified. Diversifying the supply base geographically and across multiple qualified manufacturers is a critical strategy to mitigate future single-point-of-failure risks highlighted by this recall event.
Regulatory Compliance Risk: Implications of CGMP Deviations
While the immediate action is a voluntary recall, the underlying reason—CGMP deviations, specifically out-of-specification residual solvents—signals a significant regulatory compliance risk for Micro Labs Limited. Such deviations are fundamental failures in quality assurance and manufacturing process control, which are precisely the issues the FDA targets in Warning Letters and Import Alerts. Although our knowledge graph does not indicate prior FDA Warning Letters or Import Alerts for Micro Labs Limited, this current Class II recall could serve as a precursor to heightened regulatory scrutiny. Regulatory affairs heads must advise their organizations that the FDA will expect a thorough root cause analysis and robust corrective and preventive actions (CAPA) from Micro Labs Limited. Failure to adequately address these CGMP issues could escalate to more severe enforcement actions, including an official Warning Letter, placement on an Import Alert list for products from the Verna facility, or even revocation of ANDA approvals. This event necessitates a proactive risk assessment for any company sourcing from Micro Labs Limited, focusing on the potential for future supply interruptions due to regulatory non-compliance.
Remediation Pathways and Future Market Access for Micro Labs Limited
The recall of Clobazam Tablets by Micro Labs Limited is currently 'Ongoing,' indicating that the remediation process is in its initial stages. Micro Labs Limited is now obligated to conduct a comprehensive investigation into the root cause of the residual solvent issue, implement effective corrective and preventive actions (CAPA), and demonstrate sustained compliance with CGMP regulations to the FDA. For business development executives, the speed and efficacy of this remediation will dictate Micro Labs Limited's future market access and competitive standing for Clobazam (Brand Name: CLOBAZAM). Inadequate or delayed remediation could lead to further regulatory sanctions, such as an Import Alert, which would effectively block all products from the Verna, India facility from entering the U.S. market. Supply chain VPs should anticipate potential long-term disruptions from this manufacturer and adjust their strategic sourcing plans accordingly. Regulatory affairs teams must closely monitor the FDA's public updates and Micro Labs Limited's response, as the outcome will significantly influence the reliability and viability of this supplier for the foreseeable future. This situation underscores the importance of having contingency plans for critical drug products.